Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues

  title={Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues},
  author={Vasiliki Daikopoulou and Panagiotis Apostolou and Sofia Mourati and Ioanna Vlachou and Maria Gougousi and Ioannis Papasotiriou},
Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a… 
2 Citations

Figures from this paper

Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates
Reduced susceptibility to hydroxychloroquine was not associated with viral persistence in naso-pharyngeal samples, and was associated with occurring during the second epidemic wave, which began in the summer and with strains clustering with those with a common genotype in Africa, where hydroxy chlorine was the most widely used.
2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2
The results suggest that 2′-modification couples with the protein environment to affect the structural stability, while 3′-hydrogen substitution inherently exerts “immediate termination” without compromising theStructural stability in the active site.


Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
Results provide a molecular basis for inhibition of the SARS-CoV-2 RdRp by these nucleotide analogues and if sufficient efficacy of some of these FDA-approved drugs in inhibiting viral replication in cell culture is established, they may be explored as potential COVID-19 therapeutics.
Nucleoside analogues for the treatment of coronavirus infections
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
A multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
Nucleoside analogues and nucleobases in cancer treatment.
Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
The pandemic, due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has stimulated the search for antivirals to tackle COVID-19 infection. Molecules with known pharmacokinetics and
Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections
These findings provide a solid basis for further development of an antiviral therapy for Zika virus infections, possibly exploiting a dual approach combining two different agents, one targeting the viral polymerase (direct-acting antiviral), the second targeting a host-directed autophagy mechanism.
Rational design of polymerase inhibitors as antiviral drugs.
  • B. Oberg
  • Biology, Chemistry
    Antiviral research
  • 2006
The non-nucleoside HIV reverse transcriptase inhibitors are direct inhibitors and can thus be designed in a truly rational way by use of structure information on the enzyme-inhibitor complex byUse of X-ray and NMR.
Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase
A robust in vitro nonradioactive primer extension assay is developed that provides a simple screening method that should be useful for evaluating nucleotide-based drugs targeting SARS-CoV-2 RdRp and for studying the mechanism of action of selected nucleotide analogs.
[Remdesivir, the antiviral hope against SARS-CoV-2].
  • J. Reina
  • Biology, Medicine
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
  • 2020
It seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy, however, studies and clinical trials in humans are required to know the result of their application in them.